The global battery market size for IoT is estimated to grow from USD 9.2 billion in 2020 to USD 15.9 billion in 2025; growing at a CAGR of 11.6% from 2020 to 2025

ICYMI: NEW YORK, May 25, 2020 /PRNewswire/ -- Battery market for IoT is expected to grow at CAGR of 11.6% from 2020 to 2025The global battery market size for IoT is estimated to grow from USD 9.2 billion in 2020 to USD 15.9 billion in 2025; growing at a CAGR of 11.6% from 2020 to 2025. The major factors driving the growth of the market are multi-fold rise in the use of IoT and increase in the adoption of IoT-enabled devices, increase in global demand for wireless communication, surge in R&D activities to develop advanced, flexible, and thin batteries, and rise in demand for thin and flexible batteries used in IoT-enabled devices. However, high upfront costs involved in the development of thin and flexible batteries, and the ecological implications of the disposing of battery wastes hinder the growth of the market.Read the full report: https://www.reportlinker.com/p05897405/?utm_source=PRNLithium batteries segment is expected to continue to account for largest size of battery market for IoT during forecast period.Lithium batteries have a plethora of applications in IoT devices such as wearables, home automation devices, retail, aerospace, and defense. Moreover, features such as high energy density is a key factor complementing its growth among other batteriesPrimary batteries The post The global battery market size for IoT is estimated to grow from USD 9.2 billion in 2020 to USD 15.9 billion in 2025; growing at a CAGR of 11.6% from 2020 to 2025 appeared first on Asset Management - How To Asset Manage. Seoul, Korea
http://dlvr.it/RXTGBS

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more